Clinical Efficacy and Cardiac Function Analysis of Zhigancao Decoction Combined With Metoprolol in the Treatment of Coronary Heart Disease Arrhythmias

Abstract

Objective: To explore the clinical effect and cardiac function of moxibustion licorice decoction combined with metoprolol in the treatment of coronary heart disease arrhythmia. Method: 92 patients with coronary heart disease and arrhythmia admitted from January 2022 to December 2023 were selected as the analysis subjects. Divide into a control group and an observation group using envelope randomization method. The former is treated with metoprolol, while the latter is treated with moxibustion licorice soup and metoprolol. Compare clinical efficacy, cardiac function, heart rate variability, and adverse reactions. The total effective rate of the observation group treatment was 95.65%, which was higher than that of the control group 82.61% (X2=4.039, P=0.044); The LVESD and CO levels in the observation group were lower than those in the control group, while the LVEF and LVEDD levels were higher than those in the control group (P<0.05); The number of atrial premature beats and ventricular premature beats at 24 hours in the observation group was lower than that in the control group, and the levels of SDNN and SDANN were higher than those in the control group (P<0.05); The incidence of adverse reactions in the observation group was 6.52%, which was lower than that in the control group (X2=4.389, P=0.036). Conclusion: For patients with coronary heart disease and arrhythmia, moxibustion with licorice decoction combined with metoprolol has a clear effect, can improve heart function, reduce myocardial contractility, and is relatively safe.